Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

227 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.
Mariette X, Baron G, Tubach F, Lioté F, Combe B, Miceli-Richard C, Flipo RM, Goupille P, Allez M, Salmon D, Emilie D, Carcelain G, Ravaud P. Mariette X, et al. Among authors: emilie d. Ann Rheum Dis. 2012 Nov;71(11):1783-90. doi: 10.1136/annrheumdis-2011-200408. Epub 2012 Jan 17. Ann Rheum Dis. 2012. PMID: 22258485 Clinical Trial.
Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy.
Sellam J, Hamdi H, Roy C, Baron G, Lemann M, Puéchal X, Breban M, Berenbaum F, Humbert M, Weldingh K, Salmon D, Ravaud P, Emilie D, Mariette X; RATIO (Research Axed on Tolerance of Biotherapies) Study Group. Sellam J, et al. Among authors: emilie d. Ann Rheum Dis. 2007 Dec;66(12):1610-5. doi: 10.1136/ard.2007.069799. Epub 2007 Apr 24. Ann Rheum Dis. 2007. PMID: 17456528 Free PMC article.
Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.
Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian RM, Bretagne S, Emilie D, Lemann M, Lortholary O, Mariette X; Research Axed on Tolerance of Biotherapies Group. Tubach F, et al. Among authors: emilie d. Arthritis Rheum. 2009 Jul;60(7):1884-94. doi: 10.1002/art.24632. Arthritis Rheum. 2009. PMID: 19565495 Free PMC article.
Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists.
Hamdi H, Mariette X, Godot V, Weldingh K, Hamid AM, Prejean MV, Baron G, Lemann M, Puechal X, Breban M, Berenbaum F, Delchier JC, Flipo RM, Dautzenberg B, Salmon D, Humbert M, Emilie D; RATIO (Recherche sur Anti-TNF et Infections Opportunistes) Study Group. Hamdi H, et al. Among authors: emilie d. Arthritis Res Ther. 2006;8(4):R114. doi: 10.1186/ar1994. Arthritis Res Ther. 2006. PMID: 16859506 Free PMC article.
Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease.
Pariente B, Pineton de Chambrun G, Krzysiek R, Desroches M, Louis G, De Cassan C, Baudry C, Gornet JM, Desreumaux P, Emilie D, Colombel JF, Allez M. Pariente B, et al. Among authors: emilie d. Inflamm Bowel Dis. 2012 Jul;18(7):1199-206. doi: 10.1002/ibd.21839. Epub 2011 Aug 29. Inflamm Bowel Dis. 2012. PMID: 22127789
Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study.
Krzysiek R, Breban M, Ravaud P, Prejean MV, Wijdenes J, Roy C, Henry YD, Barbey C, Trappe G, Dougados M, Emilie D; French Ankylosing Spondylitis Infliximab Network. Krzysiek R, et al. Among authors: emilie d. Arthritis Rheum. 2009 May 15;61(5):569-76. doi: 10.1002/art.24275. Arthritis Rheum. 2009. PMID: 19405015 Free article. Clinical Trial.
227 results